Eli Lilly plans to transform India into a key hub for its global supply chain, backed by a $1bn investment in contract manufacturing, as the sales of its weight-loss drug Mounjaro continue to surge. The company has introduced plans to export locally produced medications worldwide while also bringing other products, like the Alzheimer’s drug donanemab, to the Indian market. Amidst competitive pressures from companies like Novo Nordisk, Lilly is focusing on enhancing its digital and social media presence to increase awareness and expand Mounjaro’s reach beyond major cities.
